DFTX · ISSUER CIK 1813814
Definium Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 7 Definium Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $3.0M of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 6 of 6 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$3.0MInsider selling
−$3.0MNet open-market
Sep 29, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 29, 202621:15 | Sep 25, 2026 | DFTX | Chief Medical Officer, Director | S · Sell10b5-1 | $36.57 | −10,853 | 792,846 | -1% | −$397K | ||
| Sep 29, 202621:14 | Sep 25, 2026 | DFTX | Chief Executive Officer, Director | S · Sell10b5-1 | $36.57 | −31,550 | 2,213,090 | -1% | −$1.2M | ||
| Sep 29, 202621:12 | Sep 25, 2026 | DFTX | Chief Commercial Officer | S · Sell10b5-1 | $36.57 | −3,097 | 359,036 | -1% | −$113K | ||
| Sep 29, 202621:10 | Sep 25, 2026 | DFTX | Chief Legal Officer | S · Sell10b5-1 | $36.57 | −14,051 | 494,228 | -3% | −$514K | ||
| Sep 29, 202621:08 | Sep 25, 2026 | DFTX | Chief Financial Officer | S · Sell10b5-1 | $36.57 | −3,377 | 394,528 | -1% | −$123K | ||
| Sep 18, 202621:55 | Sep 18, 2026 | DFTX | Director | M · Exercise | $35.52 | +1,086 | 22,296 | +5% | $39K | ||
| Sep 18, 202621:55 | Sep 18, 2026 | DFTX | Director | M · Exercise | $35.52 | +1,629 | 21,402 | +8% | $58K | ||
| Sep 14, 202608:30 | Sep 14, 2026 | DFTX | Chief Medical Officer | A · Grant | — | +200,000 | 803,699 | +33% | — | ||
| Sep 14, 202608:30 | Sep 14, 2026 | DFTX | Chief Commercial Officer | A · Grant | — | +125,000 | 362,133 | +53% | — | ||
| Sep 14, 202608:30 | Sep 14, 2026 | DFTX | Chief Legal Officer | A · Grant | — | +125,000 | 508,279 | +33% | — | ||
| Sep 14, 202608:30 | Sep 14, 2026 | DFTX | Chief Financial Officer | A · Grant | — | +125,000 | 397,905 | +46% | — | ||
| Sep 14, 202608:30 | Sep 14, 2026 | DFTX | Chief Executive Officer, Director | A · Grant | — | +750,000 | 2,244,640 | +50% | — | ||
| Sep 4, 202621:30 | Sep 3, 2026 | DFTX | Chief Executive Officer, Director | S · Sell10b5-1 | $37.94 | −19,023 | 1,494,640 | -1% | −$722K | ||
| Sep 4, 202621:30 | Sep 2, 2026 | DFTX | Chief Executive Officer, Director | A · Grant10b5-1 | — | +40,000 | 1,513,663 | +3% | — | ||
| Aug 12, 202608:30 | Aug 12, 2026 | DFTX | Chief Executive Officer, Director | A · Grant | — | +375,000 | 1,473,246 | +34% | — | ||
| Aug 12, 202608:30 | Aug 12, 2026 | DFTX | Chief Medical Officer | A · Grant | — | +100,000 | 603,282 | +20% | — | ||
| Aug 12, 202608:30 | Aug 12, 2026 | DFTX | Chief Legal Officer | A · Grant | — | +62,500 | 383,071 | +19% | — | ||
| Aug 12, 202608:30 | Aug 12, 2026 | DFTX | Chief Commercial Officer | A · Grant | — | +62,500 | 237,133 | +36% | — | ||
| Aug 12, 202608:30 | Aug 12, 2026 | DFTX | Chief Financial Officer | A · Grant | — | +62,500 | 271,987 | +30% | — |